IRIS
AMADORI, SERGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 90.955
EU - Europa 9.192
AS - Asia 8.524
SA - Sud America 1.259
Continente sconosciuto - Info sul continente non disponibili 483
AF - Africa 124
OC - Oceania 21
Totale 110.558
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 90.583
SG - Singapore 3.571
DE - Germania 2.827
CN - Cina 2.042
UA - Ucraina 1.225
RU - Federazione Russa 1.199
IT - Italia 1.045
BR - Brasile 994
HK - Hong Kong 788
IE - Irlanda 716
GB - Regno Unito 658
VN - Vietnam 605
FR - Francia 394
KR - Corea 377
FI - Finlandia 318
SE - Svezia 314
BD - Bangladesh 284
JP - Giappone 196
CA - Canada 188
IN - India 130
PL - Polonia 121
NL - Olanda 95
AR - Argentina 78
ID - Indonesia 69
AT - Austria 61
MX - Messico 60
TR - Turchia 55
IQ - Iraq 51
ES - Italia 50
ZA - Sudafrica 43
UZ - Uzbekistan 41
EC - Ecuador 39
CO - Colombia 38
PH - Filippine 38
VE - Venezuela 37
PK - Pakistan 36
IR - Iran 34
BE - Belgio 32
JM - Giamaica 27
CL - Cile 25
SA - Arabia Saudita 25
MY - Malesia 21
CZ - Repubblica Ceca 19
AU - Australia 18
EG - Egitto 17
PE - Perù 17
PY - Paraguay 17
TH - Thailandia 17
CR - Costa Rica 16
IL - Israele 16
CH - Svizzera 15
JO - Giordania 15
LB - Libano 14
EU - Europa 13
HN - Honduras 13
TW - Taiwan 13
LT - Lituania 12
MA - Marocco 12
NP - Nepal 12
PT - Portogallo 11
UY - Uruguay 11
DK - Danimarca 10
GR - Grecia 10
NI - Nicaragua 10
NO - Norvegia 10
AE - Emirati Arabi Uniti 9
EE - Estonia 9
GT - Guatemala 9
TN - Tunisia 9
AL - Albania 8
KE - Kenya 8
SN - Senegal 8
TT - Trinidad e Tobago 8
CY - Cipro 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
KG - Kirghizistan 7
A2 - ???statistics.table.value.countryCode.A2??? 6
LA - Repubblica Popolare Democratica del Laos 6
PA - Panama 6
PS - Palestinian Territory 6
RO - Romania 6
SV - El Salvador 6
BB - Barbados 5
DM - Dominica 5
HU - Ungheria 5
NG - Nigeria 5
AO - Angola 4
AZ - Azerbaigian 4
BH - Bahrain 4
GE - Georgia 4
KZ - Kazakistan 4
MD - Moldavia 4
OM - Oman 4
QA - Qatar 4
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BO - Bolivia 3
BY - Bielorussia 3
LK - Sri Lanka 3
Totale 110.047
Salva come PNG Salva come JPEG
Città #
Woodbridge 26.937
Wilmington 22.021
Houston 18.865
Fairfield 2.504
Ashburn 2.174
Ann Arbor 2.124
Singapore 1.997
Chandler 1.365
Jacksonville 1.126
San Jose 1.106
Seattle 1.069
Cambridge 845
Dearborn 766
Hong Kong 766
Beijing 727
Dublin 696
Medford 549
New York 451
Santa Clara 402
The Dalles 331
Council Bluffs 303
Zhengzhou 298
Los Angeles 278
Dallas 271
Lawrence 257
Rome 243
Ho Chi Minh City 197
Buffalo 176
Mülheim 157
Moscow 150
Tokyo 147
Hanoi 127
San Diego 121
Lauterbourg 120
São Paulo 115
Milan 112
Menlo Park 86
Chicago 85
Munich 85
London 77
Shanghai 77
Boardman 76
Kraków 67
Denver 66
Falls Church 64
Helsinki 63
Phoenix 59
Creede 55
Hefei 55
Guangzhou 54
Nuremberg 52
Redwood City 51
Nanjing 50
Norwalk 50
North Bergen 49
Brooklyn 48
Orem 48
University Park 48
Atlanta 47
Toronto 47
Columbus 46
Montreal 46
Mountain View 43
Warsaw 41
Kunming 37
Redondo Beach 36
San Mateo 36
Rio de Janeiro 35
Frankfurt am Main 33
Palo Alto 33
Philadelphia 32
San Francisco 31
Verona 31
Nürnberg 30
Bologna 28
Chennai 28
Da Nang 28
Johannesburg 27
Hangzhou 26
Jakarta 26
Amsterdam 25
Saint Petersburg 25
Boston 24
Brussels 24
Vienna 23
Florence 22
Haiphong 22
Louisville 22
Naples 21
Newark 20
Porto Alegre 20
Mumbai 19
Miami 18
Poplar 18
Stockholm 18
Belo Horizonte 17
Manchester 17
Nanchang 17
Turin 17
Brasília 16
Totale 92.430
Salva come PNG Salva come JPEG
Nome #
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 718
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia final results of AML-13, a randomized phase-3 study 706
Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura 692
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 686
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 655
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel 584
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 572
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 552
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 547
6-phosphogluconate dehydrogenase deficiency in an Italian family 538
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 535
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 533
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 528
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 528
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 523
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 522
Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators 522
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study 520
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 518
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 515
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 515
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 511
Acute foetal distress and umbilical cord blood banking 509
High expression levels of vla-4 (CD49d) on mobilised peripheral blood stem cells are associated with rapid engraftment in multiple myeloma patients receiving autologous transplant 509
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 508
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia 507
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 507
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 506
Clinical significance of CD38 expression in chronic lymphocytic leukemia 504
Use of arsenic trioxide in haematological malignancies: Insight into the clinical development of a novel agent 503
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 499
Treatment of multiple myeloma: A randomized study of three different regimens 495
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia 494
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 492
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 491
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 489
A new system for quality control in hematopoietic progenitor cell units before reinfusion in autologous transplant 489
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 488
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 486
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 485
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 484
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 484
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 483
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 483
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 483
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 483
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse 482
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults 482
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant 482
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 480
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 480
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice 480
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 478
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 477
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 477
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 477
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience 476
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 476
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 476
Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab 474
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 474
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 473
Biological features of acute myeloid leukemia in the elderly 472
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 471
Sequential administration of gemtuzubab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-15A phase II trial 470
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 470
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 470
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 470
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 469
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 469
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura 468
Blood stem cell processing 468
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 468
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study 463
In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts 463
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 463
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia 461
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. 461
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 461
Unrelated Cord Blood transplantaion for children with high risk myelodysplastic syndrome 461
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 460
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. 460
AML-M0: a biological and clinical profile 460
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 458
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 457
Placental/Umbilical cord blood: experience of St. Eugenio Hospital collection center 455
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 455
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab 454
Induction of Apoptosis by Pyrrolobenzothiadiazepines (PBTDs) in cell lines and in 12 chronic myeloid leukaemia patients and imatinib-resistant 454
FISH analysis for CML monitoring? 454
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 453
Recurrence of a t(8;21)-positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge 453
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura 452
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 452
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825 451
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 451
Biological pattern of AML-M0 versus AML-M1: Response 451
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 451
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 451
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 450
Totale 49.505
Salva come PNG Salva come JPEG
Categoria #
all - tutte 237.803
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 237.803
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.061 0 0 0 124 72 249 134 131 141 260 149 801
2022/20233.603 402 249 210 408 280 757 336 211 399 31 243 77
2023/20241.207 139 41 62 29 146 401 86 44 15 20 23 201
2024/20255.657 213 1.374 679 301 96 239 445 285 501 450 507 567
2025/20268.993 771 428 1.178 678 723 336 1.038 1.038 1.142 906 399 356
2026/20274.061 497 793 1.848 923 0 0 0 0 0 0 0 0
Totale 110.558